Ezgi Oymak1, Ozan Cem Guler2, Cem Onal3. 1. Division of Radiation Oncology, Iskenderun Gelisim Hospital, Hatay, Turkey. 2. Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana Dr. Turgut Noyan Research and Treatment Center, 01120, Adana, Turkey. 3. Department of Radiation Oncology, Faculty of Medicine, Baskent University, Adana Dr. Turgut Noyan Research and Treatment Center, 01120, Adana, Turkey. hcemonal@hotmail.com.
Abstract
PURPOSE: This study analyzed the impact of liver metastasis (LM) volume on treatment outcomes in breast cancer (BC) patients treated with stereotactic body radiotherapy (SBRT). METHODS: This single-institution retrospective analysis included 40 oligometastatic (≤ 5 metastases) BC patients with 58 liver metastases treated with SBRT between April 2013 and March 2021. The prognostic factors for local control (LC), overall survival (OS), and progression-free survival (PFS) rates were assessed. RESULTS: Median follow-up time was 28.1 months. Isolated and solitary LM were seen in 26 (65%) and 24 (60%) patients, respectively. Median time to disease recurrence was 10.7 months post liver SBRT. The 2‑year OS, PFS, and LC rates were 71.4%, 27.5%, and 86.8%, respectively. In univariate analysis, patients with a gross tumor volume (GTV) of ≤ 6 cc and a planning target volume (PTV) of ≤ 38 cc demonstrated a significantly better median OS than those with GTV > 6 cc and PTV > 38 cc. In multivariate analysis, the predictive factors for worse OS were GTV > 6 cc (HR = 3.07 [95% CI, 1.14-8.22; p = 0.03]) and PTV > 38 cc (HR = 5.91 [95% CI, 1.92-18.21; p = 0.002]). No significant factor for PFS was found. Only 2 patients experienced rib fracture at 4 and 6 months post treatment, and 1 patient had a grade II duodenal ulcer. CONCLUSION: Liver SBRT is an effective and safe treatment option for oligometastatic BC patients with excellent LC, promising survival, and limited toxicity. Patients with smaller tumors displayed better OS than their counterparts, validating the effectiveness of a local treatment for this group.
PURPOSE: This study analyzed the impact of liver metastasis (LM) volume on treatment outcomes in breast cancer (BC) patients treated with stereotactic body radiotherapy (SBRT). METHODS: This single-institution retrospective analysis included 40 oligometastatic (≤ 5 metastases) BC patients with 58 liver metastases treated with SBRT between April 2013 and March 2021. The prognostic factors for local control (LC), overall survival (OS), and progression-free survival (PFS) rates were assessed. RESULTS: Median follow-up time was 28.1 months. Isolated and solitary LM were seen in 26 (65%) and 24 (60%) patients, respectively. Median time to disease recurrence was 10.7 months post liver SBRT. The 2‑year OS, PFS, and LC rates were 71.4%, 27.5%, and 86.8%, respectively. In univariate analysis, patients with a gross tumor volume (GTV) of ≤ 6 cc and a planning target volume (PTV) of ≤ 38 cc demonstrated a significantly better median OS than those with GTV > 6 cc and PTV > 38 cc. In multivariate analysis, the predictive factors for worse OS were GTV > 6 cc (HR = 3.07 [95% CI, 1.14-8.22; p = 0.03]) and PTV > 38 cc (HR = 5.91 [95% CI, 1.92-18.21; p = 0.002]). No significant factor for PFS was found. Only 2 patients experienced rib fracture at 4 and 6 months post treatment, and 1 patient had a grade II duodenal ulcer. CONCLUSION: Liver SBRT is an effective and safe treatment option for oligometastatic BC patients with excellent LC, promising survival, and limited toxicity. Patients with smaller tumors displayed better OS than their counterparts, validating the effectiveness of a local treatment for this group.
Authors: Erqi L Pollom; Alexander L Chin; Maximilian Diehn; Billy W Loo; Daniel T Chang Journal: Semin Radiat Oncol Date: 2017-02-20 Impact factor: 5.934
Authors: Alejandra Méndez Romero; Fatma Keskin-Cambay; Rob M van Os; Joost J Nuyttens; Ben J M Heijmen; Jan N M IJzermans; Cornelis Verhoef Journal: Rep Pract Oncol Radiother Date: 2016-12-02
Authors: M Barral; A Auperin; A Hakime; V Cartier; V Tacher; Yves Otmezguine; L Tselikas; T de Baere; F Deschamps Journal: Cardiovasc Intervent Radiol Date: 2016-02-09 Impact factor: 2.740
Authors: David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan Journal: Lancet Date: 2019-04-11 Impact factor: 79.321
Authors: Maria Franca Meloni; Anita Andreano; Paul F Laeseke; Tito Livraghi; Sandro Sironi; Fred T Lee Journal: Radiology Date: 2009-08-25 Impact factor: 11.105
Authors: Tobias F Jakobs; Ralf-Thorsten Hoffmann; Angelika Schrader; Hans Joachim Stemmler; Christoph Trumm; Andreas Lubienski; Ravi Murthy; Thomas K Helmberger; Maximilian F Reiser Journal: Cardiovasc Intervent Radiol Date: 2008-06-25 Impact factor: 2.740
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702